{"contraindications":{"vaccineGroup":{"contraindication":[{"observationCode":"094","observationTitle":"Severe allergic reaction after previous dose of Pneumococcal","contraindicationText":"Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of Pneumococcal vaccine."},{"observationCode":"080","observationTitle":"Adverse reaction to vaccine component","contraindicationText":"Do not vaccinate if the patient has had an adverse reaction to a vaccine component."}]},"vaccine":{"contraindication":[{"observationCode":"117","observationTitle":"Severe allergic reaction to diphtheria toxoid","contraindicationText":"Do not vaccinate if the patient has had a severe allergic reaction to diphtheria toxoid.","contraindicationGuidance":"n/a","contraindicatedVaccine":[{"vaccineType":"PCV13","cvx":"133"}]}]}},"series":[{"seriesName":"Pneumococcal 4-dose series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Standard","equivalentSeriesGroups":"2","selectSeries":{"defaultSeries":"Yes","productPath":"No","seriesGroupName":"Standard","seriesGroup":"1","seriesPriority":"A","seriesPreference":"1","maxAgeToStart":"12 months - 4 days"}},{"seriesName":"Pneumococcal dose 2 at 7 months series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Standard","equivalentSeriesGroups":"2","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Standard","seriesGroup":"1","seriesPriority":"A","seriesPreference":"2","maxAgeToStart":"12 months - 4 days"}},{"seriesName":"Pneumococcal start at 12 months series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Standard","equivalentSeriesGroups":"2","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Standard","seriesGroup":"1","seriesPriority":"A","seriesPreference":"3","maxAgeToStart":"24 months - 4 days"}},{"seriesName":"Pneumococcal start at 24 months series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Standard","equivalentSeriesGroups":"2","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Standard","seriesGroup":"1","seriesPriority":"A","seriesPreference":"4"}},{"seriesName":"Pneumococcal risk 2-5 years 3-dose series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPreference":"1","minAgeToStart":"2 years","maxAgeToStart":"6 years"},"indication":[{"observationCode":{"text":"Cerebrospinal fluid leaks","code":"010"},"description":"Administer to persons who have cerebrospinal fluid leaks.","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"Cochlear implants","code":"011"},"description":"Administer to persons who have cochlear implants.","beginAge":"2 years","endAge":"6 years","guidance":"When cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Diabetes","code":"014"},"description":"Administer to persons who have diabetes.","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"Chronic heart disease","code":"016"},"description":"Administer to persons who have chronic heart disease.","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"Chronic lung disease","code":"017"},"description":"Administer to persons who have chronic lung disease.","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"Asthma","code":"027"},"description":"Administer to persons who have asthma.","beginAge":"2 years","endAge":"6 years","guidance":"For patients aged 2 through 5 years, asthma is only an indication for vaccination if the patient is treated with high-dose oral corticosteroid therapy."}]},{"seriesName":"Pneumococcal risk 2-5 years 4-dose series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"D","seriesPreference":"1","minAgeToStart":"2 years","maxAgeToStart":"6 years"},"indication":[{"observationCode":{"text":"Chronic renal failure","code":"066"},"description":"Administer to persons with chronic renal failure.","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Severe antibody deficiencies","code":"145"},"description":"Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Less severe antibody deficiencies","code":"146"},"description":"Administer to persons who have less severe B-lymphocyte (humoral) - antibody deficiencies (e.g., selective IgA deficiency and IgG subclass deficiency).","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Complete defects","code":"147"},"description":"Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Partial defects","code":"148"},"description":"Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement component deficiencies, particularly C1, C2, C3, and C4 deficiencies.","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency","code":"153"},"description":"Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"Generalized malignant neoplasm","code":"156"},"description":"Administer to persons who have generalized malignant neoplasm.","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"Transplantation","code":"157"},"description":"Administer to persons who have received a transplant.","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"Immunosuppressive therapy","code":"158"},"description":"Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. ","beginAge":"2 years","endAge":"6 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Radiation therapy","code":"159"},"description":"Administer to persons who are undergoing radiation therapy.","beginAge":"2 years","endAge":"6 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"2 years","endAge":"6 years","guidance":"When elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Nephrotic Syndrome","code":"167"},"description":"Administer to persons with nephrotic syndrome.","beginAge":"2 years","endAge":"6 years"},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"2 years","endAge":"6 years"}]},{"seriesName":"Pneumococcal risk 1-dose series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"C","seriesPreference":"1","minAgeToStart":"6 years"},"indication":[{"observationCode":{"text":"Diabetes","code":"014"},"description":"Administer to persons who have diabetes.","beginAge":"6 years"},{"observationCode":{"text":"Chronic liver disease","code":"015"},"description":"Administer to persons who have chronic liver disease.","beginAge":"6 years"},{"observationCode":{"text":"Chronic heart disease","code":"016"},"description":"Administer to persons who have chronic heart disease.","beginAge":"6 years"},{"observationCode":{"text":"Chronic lung disease","code":"017"},"description":"Administer to persons who have chronic lung disease.","beginAge":"6 years"},{"observationCode":{"text":"Asthma","code":"027"},"description":"Administer to persons who have asthma.","beginAge":"6 years","guidance":"For patients aged 6 through 18 years, asthma is only an indication for vaccination if the patient is treated with high-dose oral corticosteroid therapy."},{"observationCode":{"text":"Smoke cigarettes","code":"042"},"description":"Administer to persons who smoke cigarettes.","beginAge":"19 years"},{"observationCode":{"text":"Alcoholism","code":"043"},"description":"Administer to persons who have alcoholism.","beginAge":"6 years"}]},{"seriesName":"Pneumococcal risk 2-dose PCV-PPSV series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"B","seriesPreference":"1","minAgeToStart":"6 years"},"indication":[{"observationCode":{"text":"Cerebrospinal fluid leaks","code":"010"},"description":"Administer to persons who have cerebrospinal fluid leaks.","beginAge":"6 years"},{"observationCode":{"text":"Cochlear implants","code":"011"},"description":"Administer to persons who have cochlear implants.","beginAge":"6 years","guidance":"When cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."}]},{"seriesName":"Pneumococcal risk 2-dose PPSV-PCV series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"B","seriesPreference":"2","minAgeToStart":"6 years","maxAgeToStart":"19 years"},"indication":[{"observationCode":{"text":"Cerebrospinal fluid leaks","code":"010"},"description":"Administer to persons who have cerebrospinal fluid leaks.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Cochlear implants","code":"011"},"description":"Administer to persons who have cochlear implants.","beginAge":"6 years","endAge":"19 years","guidance":"When cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."}]},{"seriesName":"Pneumococcal adult risk 2-dose PPSV-PCV series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"B","seriesPreference":"2","minAgeToStart":"19 years"},"indication":[{"observationCode":{"text":"Cerebrospinal fluid leaks","code":"010"},"description":"Administer to persons who have cerebrospinal fluid leaks.","beginAge":"19 years"},{"observationCode":{"text":"Cochlear implants","code":"011"},"description":"Administer to persons who have cochlear implants.","beginAge":"19 years"}]},{"seriesName":"Pneumococcal risk 3-dose series PCV-PPSV-PPSV","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","seriesPreference":"1","minAgeToStart":"6 years"},"indication":[{"observationCode":{"text":"Chronic renal failure","code":"066"},"description":"Administer to persons with chronic renal failure.","beginAge":"6 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Severe antibody deficiencies","code":"145"},"description":"Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).","beginAge":"6 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Less severe antibody deficiencies","code":"146"},"description":"Administer to persons who have less severe B-lymphocyte (humoral) - antibody deficiencies (e.g., selective IgA deficiency and IgG subclass deficiency).","beginAge":"6 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Complete defects","code":"147"},"description":"Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).","beginAge":"6 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Partial defects","code":"148"},"description":"Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).","beginAge":"6 years"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement component deficiencies, particularly C1, C2, C3, and C4 deficiencies.","beginAge":"6 years"},{"observationCode":{"text":"Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency","code":"153"},"description":"Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).","beginAge":"6 years"},{"observationCode":{"text":"Generalized malignant neoplasm","code":"156"},"description":"Administer to persons who have generalized malignant neoplasm.","beginAge":"6 years"},{"observationCode":{"text":"Transplantation","code":"157"},"description":"Administer to persons who have received a transplant.","beginAge":"6 years"},{"observationCode":{"text":"Immunosuppressive therapy","code":"158"},"description":"Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. ","beginAge":"6 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Radiation therapy","code":"159"},"description":"Administer to persons who are undergoing radiation therapy.","beginAge":"6 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"6 years","guidance":"When elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Nephrotic Syndrome","code":"167"},"description":"Administer to persons with nephrotic syndrome.","beginAge":"6 years"},{"observationCode":{"text":"Leukemia"},"description":"Administer to persons with leukemia.","beginAge":"6 years"},{"observationCode":{"text":"Lymphoma"},"description":"Administer to persons with lymphoma.","beginAge":"6 years"},{"observationCode":{"text":"Hodgkin's disease"},"description":"Administer to persons with Hodgkin's disease.","beginAge":"6 years"},{"observationCode":{"text":"Multiple myeloma"},"description":"Administer to persons with multiple myeloma.","beginAge":"6 years"},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"6 years"}]},{"seriesName":"Pneumococcal risk 6-18 years 3-dose PPSV23-PCV13-PPSV23 series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","seriesPreference":"2","minAgeToStart":"6 years","maxAgeToStart":"19 years"},"indication":[{"observationCode":{"text":"Chronic renal failure","code":"066"},"description":"Administer to persons with chronic renal failure.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Severe antibody deficiencies","code":"145"},"description":"Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Less severe antibody deficiencies","code":"146"},"description":"Administer to persons who have less severe B-lymphocyte (humoral) - antibody deficiencies (e.g., selective IgA deficiency and IgG subclass deficiency).","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Complete defects","code":"147"},"description":"Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Partial defects","code":"148"},"description":"Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement component deficiencies, particularly C1, C2, C3, and C4 deficiencies.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency","code":"153"},"description":"Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Generalized malignant neoplasm","code":"156"},"description":"Administer to persons who have generalized malignant neoplasm.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Transplantation","code":"157"},"description":"Administer to persons who have received a transplant.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Immunosuppressive therapy","code":"158"},"description":"Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. ","beginAge":"6 years","endAge":"19 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Radiation therapy","code":"159"},"description":"Administer to persons who are undergoing radiation therapy.","beginAge":"6 years","endAge":"19 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"6 years","endAge":"19 years","guidance":"When elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Nephrotic Syndrome","code":"167"},"description":"Administer to persons with nephrotic syndrome.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Leukemia"},"description":"Administer to persons with leukemia.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Lymphoma"},"description":"Administer to persons with lymphoma.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Hodgkin's disease"},"description":"Administer to persons with Hodgkin's disease.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Multiple myeloma"},"description":"Administer to persons with multiple myeloma.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"6 years","endAge":"19 years"}]},{"seriesName":"Pneumococcal risk adult 3-dose PPSV23-PCV13-PPSV23 series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","seriesPreference":"2","minAgeToStart":"19 years"},"indication":[{"observationCode":{"text":"Chronic renal failure","code":"066"},"description":"Administer to persons with chronic renal failure.","beginAge":"19 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Severe antibody deficiencies","code":"145"},"description":"Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).","beginAge":"19 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Less severe antibody deficiencies","code":"146"},"description":"Administer to persons who have less severe B-lymphocyte (humoral) - antibody deficiencies (e.g., selective IgA deficiency and IgG subclass deficiency).","beginAge":"19 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Complete defects","code":"147"},"description":"Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).","beginAge":"19 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Partial defects","code":"148"},"description":"Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).","beginAge":"19 years"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement component deficiencies, particularly C1, C2, C3, and C4 deficiencies.","beginAge":"19 years"},{"observationCode":{"text":"Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency","code":"153"},"description":"Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).","beginAge":"19 years"},{"observationCode":{"text":"Generalized malignant neoplasm","code":"156"},"description":"Administer to persons who have generalized malignant neoplasm.","beginAge":"19 years"},{"observationCode":{"text":"Transplantation","code":"157"},"description":"Administer to persons who have received a transplant.","beginAge":"19 years"},{"observationCode":{"text":"Immunosuppressive therapy","code":"158"},"description":"Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. ","beginAge":"19 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Radiation therapy","code":"159"},"description":"Administer to persons who are undergoing radiation therapy.","beginAge":"19 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"19 years","guidance":"When elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Nephrotic Syndrome","code":"167"},"description":"Administer to persons with nephrotic syndrome.","beginAge":"19 years"},{"observationCode":{"text":"Leukemia"},"description":"Administer to persons with leukemia.","beginAge":"19 years"},{"observationCode":{"text":"Lymphoma"},"description":"Administer to persons with lymphoma.","beginAge":"19 years"},{"observationCode":{"text":"Hodgkin's disease"},"description":"Administer to persons with Hodgkin's disease.","beginAge":"19 years"},{"observationCode":{"text":"Multiple myeloma"},"description":"Administer to persons with multiple myeloma.","beginAge":"19 years"},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"19 years"}]},{"seriesName":"Pneumococcal risk 6-18 years 3-dose PPSV23-PPSV23-PCV13 series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","seriesPreference":"3","minAgeToStart":"6 years","maxAgeToStart":"19 years"},"indication":[{"observationCode":{"text":"Chronic renal failure","code":"066"},"description":"Administer to persons with chronic renal failure.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Severe antibody deficiencies","code":"145"},"description":"Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Less severe antibody deficiencies","code":"146"},"description":"Administer to persons who have less severe B-lymphocyte (humoral) - antibody deficiencies (e.g., selective IgA deficiency and IgG subclass deficiency).","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Complete defects","code":"147"},"description":"Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Partial defects","code":"148"},"description":"Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement component deficiencies, particularly C1, C2, C3, and C4 deficiencies.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency","code":"153"},"description":"Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Generalized malignant neoplasm","code":"156"},"description":"Administer to persons who have generalized malignant neoplasm.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Transplantation","code":"157"},"description":"Administer to persons who have received a transplant.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Immunosuppressive therapy","code":"158"},"description":"Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. ","beginAge":"6 years","endAge":"19 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Radiation therapy","code":"159"},"description":"Administer to persons who are undergoing radiation therapy.","beginAge":"6 years","endAge":"19 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"6 years","endAge":"19 years","guidance":"When elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Nephrotic Syndrome","code":"167"},"description":"Administer to persons with nephrotic syndrome.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Leukemia"},"description":"Administer to persons with leukemia.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Lymphoma"},"description":"Administer to persons with lymphoma.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Hodgkin's disease"},"description":"Administer to persons with Hodgkin's disease.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"Multiple myeloma"},"description":"Administer to persons with multiple myeloma.","beginAge":"6 years","endAge":"19 years"},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"6 years","endAge":"19 years"}]},{"seriesName":"Pneumococcal risk adult 3-dose PPSV23-PPSV23-PCV13 series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","seriesPreference":"3","minAgeToStart":"19 years"},"indication":[{"observationCode":{"text":"Chronic renal failure","code":"066"},"description":"Administer to persons with chronic renal failure.","beginAge":"19 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Severe antibody deficiencies","code":"145"},"description":"Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).","beginAge":"19 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Less severe antibody deficiencies","code":"146"},"description":"Administer to persons who have less severe B-lymphocyte (humoral) - antibody deficiencies (e.g., selective IgA deficiency and IgG subclass deficiency).","beginAge":"19 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Complete defects","code":"147"},"description":"Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).","beginAge":"19 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Partial defects","code":"148"},"description":"Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).","beginAge":"19 years"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement component deficiencies, particularly C1, C2, C3, and C4 deficiencies.","beginAge":"19 years"},{"observationCode":{"text":"Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency","code":"153"},"description":"Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).","beginAge":"19 years"},{"observationCode":{"text":"Generalized malignant neoplasm","code":"156"},"description":"Administer to persons who have generalized malignant neoplasm.","beginAge":"19 years"},{"observationCode":{"text":"Transplantation","code":"157"},"description":"Administer to persons who have received a transplant.","beginAge":"19 years"},{"observationCode":{"text":"Immunosuppressive therapy","code":"158"},"description":"Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. ","beginAge":"19 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Radiation therapy","code":"159"},"description":"Administer to persons who are undergoing radiation therapy.","beginAge":"19 years","guidance":"When immunocompromising therapy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"19 years","guidance":"When elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy."},{"observationCode":{"text":"Nephrotic Syndrome","code":"167"},"description":"Administer to persons with nephrotic syndrome.","beginAge":"19 years"},{"observationCode":{"text":"Leukemia"},"description":"Administer to persons with leukemia.","beginAge":"19 years"},{"observationCode":{"text":"Lymphoma"},"description":"Administer to persons with lymphoma.","beginAge":"19 years"},{"observationCode":{"text":"Hodgkin's disease"},"description":"Administer to persons with Hodgkin's disease.","beginAge":"19 years"},{"observationCode":{"text":"Multiple myeloma"},"description":"Administer to persons with multiple myeloma.","beginAge":"19 years"},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"19 years"}]},{"seriesName":"Pneumococcal 65+ 1-dose PPSV23","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Standard","equivalentSeriesGroups":"2","selectSeries":{"defaultSeries":"Yes","productPath":"No","seriesGroupName":"Standard 65+","seriesGroup":"3","seriesPriority":"A","seriesPreference":"1","minAgeToStart":"65 years"}},{"seriesName":"Pneumococcal 65+ 2-dose PCV13-PPSV23 series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Standard","equivalentSeriesGroups":"2","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Standard 65+","seriesGroup":"3","seriesPriority":"A","seriesPreference":"2","minAgeToStart":"65 years"}},{"seriesName":"Pneumococcal 65+ 2-dose PPSV23-PCV13 series","targetDisease":"Pneumococcal","vaccineGroup":"Pneumococcal","seriesType":"Standard","equivalentSeriesGroups":"2","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Standard 65+","seriesGroup":"3","seriesPriority":"A","seriesPreference":"3","minAgeToStart":"65 years"}}]}